Oncology · DLBCLTrial Updateclinicalmid-term

Single-Arm Study of Zeprumetostat with Glofitamab in Relapsed/Refractory DLBCL

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/31/2026, 6:31:51 AM

Assessment confidence: 68% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial for Zeprumetostat in combination with Glofitamab and GemOx could significantly influence treatment options in the DLBCL space. Its outcomes may reshape competitive dynamics and inform portfolio strategies for oncology-focused pharma companies. Regulatory context from FDA (Verified Clinical Benefit | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 24 ranked evidence items (13 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential of Zeprumetostat in combination therapies and its impact on market positioning in DLBCL. The strongest clinical anchor is Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (ClinicalTrials.gov), sponsor/company relevance (merck); patient population match (refractory). In Oncology · DLBCL, 4 regulatory and 5 competitive items passed relevance filtering for Zeprumetostat.

Competitive Pressure

Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial.

Regulatory Outlook

Regulatory risk is concentrated around Verified Clinical Benefit | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). The trial results will be critical for potential regulatory submissions and could affect labeling and approval timelines for the combination therapy.

Key Risks

Elevated medium regulatory exposure for Zeprumetostat could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Cancer Clinical Trial Eligibility Criteria: Laboratory Values) could weigh on Zeprumetostat through agency review timelines and labeling constraints if follow-through weakens.
Regulatory risk from FDA (Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications) could weigh on Zeprumetostat through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If successful, this combination therapy could enhance market share for the involved products and provide a competitive edge in the DLBCL treatment landscape.
Bristol Myers Squibb document relevant to the signal.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Upside for Zeprumetostat may improve if Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Laboratory Values
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck); Patient population match (refractory)
FDA document
View source
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Evaluate the Effects of the Edge+Ease PM+AM System on Mood, Mental Clarity, Sleep Quality, and Digestive Wellbeing
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)

Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
High-flow nasal cannula oxygenation in sedated endoscopy for high-risk obstructive sleep apnea patients: study protocol for a multicentre randomised controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of probiotics on humoral responses to COVID-19 vaccination in older adults: a randomized, placebo-controlled trial (PIRATES-COV study).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Zeprumetostat
Glofitamab

Commercial impact

medium

If successful, this combination therapy could enhance market share for the involved products and provide a competitive edge in the DLBCL treatment landscape.

Regulatory impact

medium

The trial results will be critical for potential regulatory submissions and could affect labeling and approval timelines for the combination therapy.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.